Lazard Downgrades American Oriental (AOB) to Hold
More News related to AOB
- China Aoxing Pharmaceutical Company to Present at Brean Murray, Carret & Co. 2009 China Growth Conference
- American Oriental Bioengineering to Report Third Quarter 2009 Financial Results on November 16, 2009
- China Aoxing Pharmaceutical Company to Present at 2009 China Growth Conference of Adam Friedman Associates on October 28, 2009
- China Aoxing Pharmaceutical Company Reports Fiscal Year 2009 Financial Results
- American Oriental (AOB) Files S-3 to Sell Up to 150M in Shelf Sale
More News related to Downgrades
- Standpoint Research Downgraded Deckers Outdoor (DECK) to Hold
- BGB Securities Downgrades Helmerich & Payne (HP) to Sell
- Sidoti & Co Downgrades Waste Services (WSII) to Neutral
- William Blair Downgrades Strayer (STRA), ITT (ESI) to Market Perform
- D.A. Davidson Downgrades Rocky Brands (RCKY) to Underperform
Lazard Capital downgrades American Oriental Bioengineering (NYSE: AOB) from Buy to Hold.
American Oriental Bioengineering, Inc., together with its subsidiaries, engages in the development, manufacture, and commercialization of a range of pharmaceutical and healthcare products.
Related Categories
DowngradesStocks Mentioned
+0.06Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
